PolyPeptide Group AG (CH:PPGN)
:PPGN
Want to see CH:PPGN full AI Analyst Report?
PPGN Stock Chart & Stats
CHF29.80
CHF1.30(6.77%)
At close: 4:00 PM EST
CHF29.80
CHF1.30(6.77%)
Day’s Range― - ―
52-Week RangeCHF18.20 - CHF38.80
Previous CloseN/A
Volume22.87K
Average Volume (3M)34.07K
Market Cap
CHF1.26B
Enterprise ValueCHF1.38B
Total Cash (Recent Filing)CHF74.53M
Total Debt (Recent Filing)CHF130.46M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 13, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio-5.12
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF39.67Price Target Upside33.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.66
Revenue Forecast (FY)CHF482.27M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSteady revenue growth (including +6.2% in 2025) indicates expanding commercial traction in peptide CDMO services. Durable top-line expansion supports scale economics, underpins capacity investments, and raises the probability of sustained margin recovery if commercial supply mix increases.
Improving Operating Cash FlowImproving operating cash flow across 2024–2025 demonstrates the business is generating core cash despite accounting losses. Reliable operational cash generation reduces near-term funding pressure, helps fund working capital and capex for capacity expansion, and supports a path to durable self-funding.
Specialized Peptide CDMO NicheA specialist focus on peptide APIs and end-to-end services creates high technical barriers, regulatory know-how, and customer stickiness. This niche positioning benefits from secular peptide demand, enabling repeat commercial supply contracts and pricing power versus generalist manufacturers over the medium term.
Bears Say
Persistent Net LossesContinued net losses through 2025 show the profitability recovery remains incomplete. Losses have eroded equity and limit retained-capital reinvestment, meaning sustainable earnings improvement must arrive to convert revenue growth and OCF gains into lasting profitability and reduce reliance on external funding.
Rising LeverageA meaningful increase in leverage narrows financial flexibility and raises interest and covenant risks. Higher debt makes funding large capacity projects more expensive and reduces resilience to operational setbacks, increasing the importance of consistent cash flow and margin improvement to stabilize the capital structure.
Volatile Free Cash FlowSharp swings in free cash flow—including a large negative in 2025—signal heavy investment and working-capital variability. That volatility undermines the company’s ability to self-fund growth consistently, elevates refinancing risk during downturns, and increases execution risk for capacity expansions.
PolyPeptide Group AG News
PPGN FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was CHF18.20 and its highest was CHF38.80 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF1.26B.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Aug 13, 2026 which is in 102 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Mar 12, 2026. The company reported CHF0.152 earnings per share for the quarter, missing the consensus estimate of CHF0.268 by -CHF0.116.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Undervalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of N/A. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is -0.31.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of CHF0.152 in its last earnings report, missing expectations of CHF0.268. Following the earnings report the stock price went up 8.776%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in CH:PPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
PPGN Stock 12 Month Forecast
Average Price Target
CHF39.67
▲(33.11% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Galderma Group AG
―
Options Prices
Currently, No data available
---